RxDoctor Payments Data

Suzanne Hartmann

Acute Care · Raleigh, NCNPI 1558617134

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 678 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,467in general payments, 2019–2025

Across 678 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$1K
  • Lundbeck LLC$713
  • MDD US Operations, LLC$648
  • Teva Pharmaceuticals USA, Inc.$585
  • Pfizer$576
  • plus $6K from 51 others

What the payments were for

  • Consulting fees$4504%
  • Food & beverage$12,01796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)141$2,789
UCB, Inc.57$1,076
Lundbeck LLC30$713
MDD US Operations, LLC47$648
Teva Pharmaceuticals USA, Inc.40$585
Pfizer31$576
Neurocrine Biosciences, Inc.26$442
Novartis20$407
Amgen23$400
Eisai Inc.21$389
AstraZeneca(2 entities)19$385
Impel Pharmaceuticals Inc.23$364
Biogen18$318
Johnson & Johnson(2 entities)11$200
Sanofi9$197
Merz Pharmaceuticals, LLC9$195
Neurelis, Inc.9$180
Boston Scientific2$179
Axsome Therapeutics, Inc.9$158
Biohaven Pharmaceutical Holding Company Ltd.9$152
Otsuka America Pharmaceutical, Inc.6$120
Bristol Myers Squibb7$115
EMD Serono, Inc.5$112
Acadia Pharmaceuticals Inc6$108
TG Therapeutics, Inc.4$103
Ipsen Biopharmaceuticals, Inc5$99
Aucta Pharmaceuticals, Inc.8$99
Lilly USA, LLC7$96
Supernus Pharmaceuticals, Inc.6$88
Sunovion Pharmaceuticals Inc.6$85
Grifols USA, LLC5$85
Catalyst Pharmaceuticals, Inc.3$78
Amneal Pharmaceuticals LLC5$76
Biohaven Pharmaceuticals, Inc.5$75
Kyowa Kirin, Inc.4$71
Corium, LLC5$66
Upsher-smith Laboratories LLC4$60
Banner Life Sciences, LLC3$60
Acorda Therapeutics, Inc3$51
Genentech USA, Inc.3$43
Argenx US, Inc.2$40
Sumitomo Pharma America, Inc.2$36
Alnylam Pharmaceuticals Inc.2$35
Microtransponder, Inc.2$35
Avion Pharmaceuticals2$35
GRT US Holding, Inc.2$34
SK Life Science, Inc.1$30
GE HealthCare2$25
Jazz Pharmaceuticals Inc.1$22
Takeda Pharmaceuticals U.S.A., Inc.1$21
CSL Behring1$18
Idorsia Pharmaceuticals US Inc1$17
Cala Health, Inc.1$16
Arbor Pharmaceuticals, Inc.1$16
Averitas Pharma Inc.1$16
Collegium Pharmaceutical, Inc.1$15
Adamas Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,467 in reported general payments places this provider in the 95th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,104
Medicare patients
345
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate33$42,456
UbrelvyUbrogepant20$26,518
Aimovig AutoinjectorErenumab-Aooe23$24,202
QuliptaAtogepant14$17,289
Emgality PenGalcanezumab-Gnlm15$15,949
Lacosamide77$12,418
Levetiracetam227$7,720
Dalfampridine ErDalfampridine12$6,609
Gabapentin190$4,589
Baclofen96$2,736
Dimethyl Fumarate13$2,320
Divalproex Sodium ErDivalproex Sodium24$1,981
Oxcarbazepine37$1,977
Memantine Hcl64$1,582
Phenytoin Sodium Extended20$1,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,789$43,80734 claims
PfizerNurtec Odt$576$42,45633 claims
Upsher-smith Laboratories LLCTopiramate$60$48329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 acute care providers in North Carolina.

Other acute care in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →